CN112654356A - 增加四氢生物蝶呤血浆暴露的组合物和方法 - Google Patents

增加四氢生物蝶呤血浆暴露的组合物和方法 Download PDF

Info

Publication number
CN112654356A
CN112654356A CN201980050730.3A CN201980050730A CN112654356A CN 112654356 A CN112654356 A CN 112654356A CN 201980050730 A CN201980050730 A CN 201980050730A CN 112654356 A CN112654356 A CN 112654356A
Authority
CN
China
Prior art keywords
subject
food
sepiapterin
effective amount
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050730.3A
Other languages
English (en)
Chinese (zh)
Inventor
N·史密斯
J·雷斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ptc Medical Mp Co
Original Assignee
Ptc Medical Mp Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Medical Mp Co filed Critical Ptc Medical Mp Co
Publication of CN112654356A publication Critical patent/CN112654356A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980050730.3A 2018-05-30 2019-05-30 增加四氢生物蝶呤血浆暴露的组合物和方法 Pending CN112654356A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862677926P 2018-05-30 2018-05-30
US62/677926 2018-05-30
US201862771397P 2018-11-26 2018-11-26
US62/771397 2018-11-26
US201962822365P 2019-03-22 2019-03-22
US62/822365 2019-03-22
GC2019/37662 2019-05-28
GC201937662 2019-05-28
PCT/US2019/034515 WO2019232126A1 (en) 2018-05-30 2019-05-30 Compositions and methods for increasing tetrahydrobiopterin plasma exposure

Publications (1)

Publication Number Publication Date
CN112654356A true CN112654356A (zh) 2021-04-13

Family

ID=68699016

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050730.3A Pending CN112654356A (zh) 2018-05-30 2019-05-30 增加四氢生物蝶呤血浆暴露的组合物和方法

Country Status (22)

Country Link
US (2) US12257252B2 (cg-RX-API-DMAC10.html)
EP (2) EP3801534B1 (cg-RX-API-DMAC10.html)
JP (2) JP7547215B2 (cg-RX-API-DMAC10.html)
CN (1) CN112654356A (cg-RX-API-DMAC10.html)
BR (1) BR112020024329A2 (cg-RX-API-DMAC10.html)
CA (1) CA3102105A1 (cg-RX-API-DMAC10.html)
DK (1) DK3801534T3 (cg-RX-API-DMAC10.html)
ES (1) ES3068414T3 (cg-RX-API-DMAC10.html)
FI (1) FI3801534T3 (cg-RX-API-DMAC10.html)
FR (1) FR26C1028I1 (cg-RX-API-DMAC10.html)
HR (1) HRP20260360T1 (cg-RX-API-DMAC10.html)
LT (2) LT3801534T (cg-RX-API-DMAC10.html)
MD (1) MD3801534T2 (cg-RX-API-DMAC10.html)
MX (1) MX2020012980A (cg-RX-API-DMAC10.html)
NL (1) NL301382I2 (cg-RX-API-DMAC10.html)
NO (1) NO2026028I1 (cg-RX-API-DMAC10.html)
PL (1) PL3801534T3 (cg-RX-API-DMAC10.html)
PT (1) PT3801534T (cg-RX-API-DMAC10.html)
RS (1) RS68045B1 (cg-RX-API-DMAC10.html)
SI (1) SI3801534T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202600220T1 (cg-RX-API-DMAC10.html)
WO (1) WO2019232126A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
WO2018102315A1 (en) 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
MX2020002271A (es) 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7778477B2 (ja) 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
JP7502197B2 (ja) * 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
CA3165636A1 (en) * 2020-01-24 2021-07-29 Neil Smith Methods for treating parkinson's disease with sepiapterin
US12691119B2 (en) 2021-02-09 2026-07-28 Ptc Therapeutics Mp, Inc. Methods for treating covid-19 with sepiapterin
US12298026B1 (en) 2021-04-12 2025-05-13 W. L. Gore & Associates, Inc. Latent energy transfer laminate for plate pack core

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678025A (zh) * 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
US20130108694A1 (en) * 2011-11-02 2013-05-02 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20130197000A1 (en) * 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
CN103458900A (zh) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5925323A (ja) 1982-03-03 1984-02-09 鐘淵化学工業株式会社 プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
WO1997007236A1 (en) 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US8188043B2 (en) 1999-07-28 2012-05-29 The Board Of Trustees Of The Leland Stanford Jr. University Nicotine in therapeutic angiogenesis and vasculogenesis
FR2859996B1 (fr) 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
CA2545968C (en) 2003-11-17 2010-03-09 Merck Eprova Ag Crystalline forms of (6r)-l-erythro-tetrahydrobiopterin dihydrochloride
JP5184783B2 (ja) 2003-11-17 2013-04-17 バイオマリン ファーマシューティカル インコーポレイテッド テトラヒドロビオプテリン、及びテトラヒドロビオプテリン類似体の製造方法
PT3138566T (pt) 2003-11-17 2022-02-02 Biomarin Pharm Inc Tratamento de fenilcetonúria com bh4
CN101132776A (zh) 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
US20100130500A1 (en) 2004-12-08 2010-05-27 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
WO2006118322A1 (en) 2005-04-28 2006-11-09 Shiratori Pharmaceutical Co., Ltd. Method for producing hydrazone derivatives
US20080075666A1 (en) 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
WO2010017570A2 (de) 2008-08-12 2010-02-18 Orpha Swiss Gmbh Pharmazeutische darreichungsform enthaltend tetrahydrobiopterin
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
JP6084967B2 (ja) 2012-05-07 2017-02-22 白鳥製薬株式会社 セピアプテリン及びテトラヒドロラクトイルプテリンの製造法
EP3213062B1 (en) 2014-10-31 2020-02-12 Children's Medical Center Corporation Methods and assays relating to sepiapterin reductase inhibition
WO2018102315A1 (en) * 2016-11-29 2018-06-07 Censa Pharmaceuticals Inc. Polymoprhs of sepiapterin and salts thereof
CN110312721A (zh) 2016-11-29 2019-10-08 显莎制药公司 墨蝶呤的多晶型物
MX2020002271A (es) * 2017-09-01 2020-10-05 Ptc Therapeutics Mp Inc Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
JP7778477B2 (ja) * 2018-05-30 2025-12-02 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンの薬学的に許容される塩
CA3102105A1 (en) 2018-05-30 2019-12-05 Ptc Therapeutics Mp, Inc. Compositions and methods for increasing tetrahydrobiopterin plasma exposure
JP7502197B2 (ja) 2018-05-30 2024-06-18 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリン血漿曝露を増加させるための方法
LT4009978T (lt) 2019-08-05 2024-11-25 Ptc Therapeutics Mp, Inc. Sepiapterino ir jo metabolitų panaudojimas spinduliuotės poveikio gydymui
IL291565B1 (en) 2019-09-25 2026-04-01 Ptc Therapeutics Inc Method for treating phenylalanine irregularity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678025A (zh) * 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
US20130197000A1 (en) * 2010-04-22 2013-08-01 Nihon University Drug and food/drink for preventing or improving cerebral dysfunction
CN103458900A (zh) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物
US20130108694A1 (en) * 2011-11-02 2013-05-02 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. NIEDERWIESER，等: "Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin, screening and study of biosynthesis in man", EUR J PEDIATR, vol. 138, 31 December 1982 (1982-12-31), pages 110 - 112 *
王琳;喻唯民;李晓雯;贺春;常明;沈明;赵世萍;付桂香;沈抒;刘孜孜;萧广仁;: "中国北方人群四氢生物蝶呤缺乏症的研究", 中华医学遗传学杂志, no. 03, 26 June 2006 (2006-06-26), pages 37 - 41 *
石晓峰，等: "墨蝶呤对糖尿病胃轻瘫大鼠胃排空影响及其机制", 青岛大学医学院学报 ., vol. 50, no. 01, 14 January 2014 (2014-01-14), pages 10 - 12 *

Also Published As

Publication number Publication date
CA3102105A1 (en) 2019-12-05
EP4748370A2 (en) 2026-05-27
PL3801534T3 (pl) 2026-07-06
FR26C1028I1 (fr) 2026-07-17
JP7547215B2 (ja) 2024-09-09
JP2021525746A (ja) 2021-09-27
EP4748370A3 (en) 2026-07-29
ES3068414T3 (en) 2026-05-29
EP3801534A1 (en) 2021-04-14
SMT202600220T1 (it) 2026-07-16
JP7855033B2 (ja) 2026-05-07
US20210161901A1 (en) 2021-06-03
SI3801534T1 (sl) 2026-06-30
LTPA2026521I1 (cg-RX-API-DMAC10.html) 2026-06-10
US20250195529A1 (en) 2025-06-19
JP2024178188A (ja) 2024-12-24
NO2026028I1 (no) 2026-05-29
MX2020012980A (es) 2021-04-29
FI3801534T3 (fi) 2026-04-14
LT3801534T (lt) 2026-05-25
NL301382I2 (nl) 2026-07-16
EP3801534B1 (en) 2026-02-18
MD3801534T2 (en) 2026-07-31
US12257252B2 (en) 2025-03-25
EP3801534A4 (en) 2022-03-16
WO2019232126A1 (en) 2019-12-05
RS68045B1 (sr) 2026-05-29
HRP20260360T1 (hr) 2026-06-05
DK3801534T3 (da) 2026-03-30
BR112020024329A2 (pt) 2021-02-23
PT3801534T (pt) 2026-04-28

Similar Documents

Publication Publication Date Title
US20250195529A1 (en) Compositions and methods for increasing tetrahydrobiopterin plasma exposure
US12329757B2 (en) Methods for increasing sepiapterin plasma exposure
US12213982B2 (en) Pharmaceutical compositions comprising sepiapterin and uses thereof
KR20210038848A (ko) 세피아프테린의 제약상 허용되는 염
TW202245780A (zh) 用於治療神經膠質母細胞瘤之方法
US20240122931A1 (en) Methods for treating covid-19 with sepiapterin
HK40119071A (en) Methods for increasing sepiapterin plasma exposure
HK40051961B (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
HK40051961A (en) Administration of sepiapterin without food for use in a method for increasing sepiapterin plasma exposure
BR112020024346A2 (pt) métodos para aumentar a exposição de sepiapterina no plasma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination